Despite changes, generics continue to face obstacles in Japan

05/21/2013 | BioSpectrum Asia

Although Japan is the world's second-largest pharmaceutical market after the U.S., generics represent only 6.6% of prescription drug sales, largely because of public attitudes skeptical of the effectiveness and safety of unfamiliar brands, especially if the drugs are produced in countries such as India and China. Several factors may help change these views: government efforts to further cut generic-drug prices, higher reimbursements for generics, patent expirations and a rapidly aging population.

View Full Article in:

BioSpectrum Asia

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX